c-Met is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
== Rhabdomyolysis == Exertional rhabdomyolysis is an extreme and potentially deadly form of overtraining that leads to a breakdown of skeletal muscle which makes its way into the blood. Many molecules such as potassium, creatine kinase, phosphate, and myoglobin are released into circulation. Myoglobin is the protein that causes the lethal reaction in the body. Early detection of the syndrome is essential in full recovery. A serious late complication of rhabdomyolysis which occurs in 15% of the population is acute kidney injury, and in some cases it can lead to death.
==== 1300–1399 ==== Concession Statements (Prescribed Information) Regulations 1993 (S.I. 1993/1300) Gipsy Encampments (City of Hereford) Order 1993 (S.I. 1993/1301) South Wales Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1302) Dyfed-Powys Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1303) Seed Potatoes (Fees) (Scotland) Regulations 1993 (S.I. 1993/1311) Eastwood and East Kilbride Districts (Busby) Boundaries Amendment Order 1993 (S.I. 1993/1312) Margate Pier and Harbour Revision Order 1992 (SI 1993/1313) Integrated Administration and Control System Regulations 1993 (S.I. 1993/1317) Lewisham and Southwark (London Borough Boundaries) Order 1993 (S.I. 1993/1318) Greater London and Surrey (County and London Borough Boundaries) (No.3) Order 1993 (S.I. 1993/1319) Plant Health (Great Britain) Order 1993 (S.I. 1993/1320) Health and Safety (Fees) Regulations 1993 (S.I. 1993/1321) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass and Slip Road) Order 1993 (S.I. 1993/1322) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass) (Detrunking) Order 1993 (S.I. 1993/1323) Post Office (Abolition of Import Restrictions) Regulations 1993 (S.I. 1993/1324) Fishing Vessels (Safety Improvements) (Grants) Scheme 1993 (S.I. 1993/1325) Insurance Companies (Cancellation) Regulations 1993 (S.I. 1993/1327) Diseases of Animals (Therapeutic Substances) (Revocation) Order 1993 (S.I. 1993/1331) Foot-and-Mouth Disease (Sera and Glandular Products) (Revocation) Order 1993 (S.I.
== History == In the 17th century, copper miners in Saxony, Germany, began to experience irritation caused by a "dark red ore". Since the substance, which would later be called nickel, led to many ailments, they believed it to be protected by "goblins", and called it "Goblin's Copper". Josef Jadassohn described the first case of metal contact dermatitis in 1895, to a mercury-based therapeutic cream, and confirmed the cause by epicutaneous patch testing. In the next century nickel began to be mass-produced for jewelry worldwide due to its cheap cost, resistance to corrosion and high supply. American Metal Market predicted in 2001 that concerns about the health effects of nickel and the use of nickel-free Nordic gold in the Euro would impact the nickel market, estimating 50,000 to 70,000 tonnes of nickel would be scrapped from obsolete coinage in 2002. A large comprehensive study of healthy US volunteers in 1979 found that 9% had been unknowingly sensitized to nickel. As of 2008, that number has tripled. Most importantly, nickel allergy among children is increasing, with an estimated 250,000 children sensitized to nickel. Published literature shows an exponential increase in reported nickel allergy cases. The North American Contact Dermatitis Group (NACDG) patch tested 5,085 adults, presenting with eczema-like symptoms, showing 19.5% had a positive reaction to nickel. Nickel allergy is also more prevalent in women (17.1%) than men (3%), possibly due to cultural norms related to jewelry and ear piercings and therefore increased exposure to nickel.
Following its reconstitution under the Local Government Act 1972, elections were held for Lancashire County Council on 12 April 1973. All 94 wards were up for election and all wards returned one councillor by FPTP, with the exception of Preston No. 1 and Preston No. 4, which returned two councillors each by plurality block voting. A Conservative majority was returned.
Gly + [Glu(-Cys)]n+1-Gly Thus, the two substrates of this enzyme are glutathione and [Glu(-Cys)]n-Gly, whereas its two products are Gly and [Glu(-Cys)]n+1-Gly. This enzyme belongs to the family of transferases, specifically the aminoacyltransferases. The systematic name of this enzyme class is glutathione:poly(4-glutamyl-cysteinyl)glycine 4-glutamylcysteinyltransferase. Other names in common use include phytochelatin synthase, and gamma-glutamylcysteine dipeptidyl transpeptidase.
Sources: en.wikipedia.org
== See also == Prokaryotic elongation factors EF-Ts (elongation factor thermo stable) EF-Tu (elongation factor thermo unstable) EF-P (elongation factor P) eEF2 (eukaryotic elongation factor 2) Protein translation GTPase
==== Cable bandwidth and certifications ==== Not all DisplayPort cables are capable of functioning at the highest levels of bandwidth. Cables may be submitted to VESA for an optional certification at various bandwidth levels. VESA offers five levels of cable certification: Standard, DP8K, DP40, DP54, and DP80. These certify DisplayPort cables for proper operation at the following speeds:
== External links == Protamine+Sulfate at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Protamine Sulfate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on August 29, 2021.
Silica monoliths, on the other hand, are created in a mold, undergo a significant amount of shrinkage, and are then clad in a polymeric shrink tubing like PEEK (polyetheretherketone) to reduce wall effects. This method limits the size of columns that can be produced to less than 15 cm long, and though standard analytical inner diameters are readily achieved, there is currently a trend in developing nanoscale capillary and prep scale silica monoliths.
12 September Your Flight in Their Hands, about aviation safety in Europe; over a million passenger flights occurred in the UK each year in the early 1990s, but no crash due to ATC error has taken place; flights were expected to double in 20 years; the technology being deployed in UK airspace, with Gordon Doggett, head of the London Area Control Centre (LATCC); Keith Mack, the Director-General from 1988 to 1993 of Eurocontrol; a British Airways Boeing 737 BA466 takes a route over Ortac to Madrid; Karl-Heinz Neumeister, the Secretary-General of the Association of European Airlines; the aviation writer Rigas Doganis. Directed by Richard Vaughan, produced by Chris Haws, made by InCA Productions 19 September Fear of Falling, about rock climbing and caving equipment; the single-rope technique (SRT), demonstrated by Nigel Atkins of Pennine National Caving, with a dynamic climbing rope, maillon rapide, snap-gate carabiner, ascender and descender; Ben Lyon of Tebay; a climbing harness, designed by Don Whillans, and the belay loop at Troll Safety Equipment (later Bacou-Dalloz, bought by Sperian of France) in Saddleworth; Simon Nadin; the Foundry indoor climbing centre, opened by Jerry Moffatt in 1991; Undercover Rock at St Werburgh's Church, Bristol; sport climbing; Ben Moon in Derbyshire. Directed by Steve Stevenson, produced by Mike Wallington, made by Parvenu Productions 3 October Family Fortunes, about how children's mental development or health is affected or hindered by growing up in a one-parent-family.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.